IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v6y2015i1d10.1038_ncomms7377.html
   My bibliography  Save this article

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Author

Listed:
  • Matthew J. Niederst

    (Massachusetts General Hospital Cancer Center, Massachusetts General Hospital
    Harvard Medical School)

  • Lecia V. Sequist

    (Massachusetts General Hospital Cancer Center, Massachusetts General Hospital
    Harvard Medical School)

  • John T. Poirier

    (Memorial Sloan Kettering Cancer Center, Thoracic Oncology Service)

  • Craig H. Mermel

    (Broad Institute of MIT and Harvard, Cancer Genome Comparative Analysis Group
    Massachusetts General Hospital Cancer Center)

  • Elizabeth L. Lockerman

    (Massachusetts General Hospital Cancer Center, Massachusetts General Hospital
    Harvard Medical School)

  • Angel R. Garcia

    (Massachusetts General Hospital Cancer Center, Massachusetts General Hospital
    Harvard Medical School)

  • Ryohei Katayama

    (Massachusetts General Hospital Cancer Center, Massachusetts General Hospital
    Harvard Medical School)

  • Carlotta Costa

    (Massachusetts General Hospital Cancer Center, Massachusetts General Hospital
    Harvard Medical School)

  • Kenneth N. Ross

    (Massachusetts General Hospital Cancer Center, Massachusetts General Hospital
    Harvard Medical School)

  • Teresa Moran

    (Massachusetts General Hospital Cancer Center, Massachusetts General Hospital
    Harvard Medical School
    Present address: Catalan Institute of Oncology, Avinguda de la Granvia de l’Hospitalet, 199-203, 08907 Barcelona, Spain)

  • Emily Howe

    (Massachusetts General Hospital Cancer Center, Massachusetts General Hospital
    Harvard Medical School)

  • Linnea E. Fulton

    (Massachusetts General Hospital Cancer Center, Massachusetts General Hospital
    Harvard Medical School)

  • Hillary E. Mulvey

    (Massachusetts General Hospital Cancer Center, Massachusetts General Hospital
    Harvard Medical School)

  • Lindsay A. Bernardo

    (Massachusetts General Hospital Cancer Center
    Harvard Medical School)

  • Farhiya Mohamoud

    (Massachusetts General Hospital Cancer Center, Massachusetts General Hospital
    Harvard Medical School)

  • Norikatsu Miyoshi

    (Harvard Medical School
    Molecular Profiling Laboratory, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital)

  • Paul A. VanderLaan

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Daniel B. Costa

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Pasi A. Jänne

    (Belfer Institute of Applied Science, Dana Farber Cancer Institute
    Brigham and Women’s Hospital and Harvard Medical School)

  • Darrell R. Borger

    (Massachusetts General Hospital Cancer Center, Massachusetts General Hospital
    Harvard Medical School)

  • Sridhar Ramaswamy

    (Massachusetts General Hospital Cancer Center, Massachusetts General Hospital
    Harvard Medical School
    Broad Institute of MIT and Harvard, Cancer Genome Comparative Analysis Group)

  • Toshi Shioda

    (Harvard Medical School
    Molecular Profiling Laboratory, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital)

  • Anthony J. Iafrate

    (Massachusetts General Hospital Cancer Center
    Harvard Medical School)

  • Gad Getz

    (Harvard Medical School
    Broad Institute of MIT and Harvard, Cancer Genome Comparative Analysis Group
    Massachusetts General Hospital Cancer Center)

  • Charles M. Rudin

    (Memorial Sloan Kettering Cancer Center, Thoracic Oncology Service)

  • Mari Mino-Kenudson

    (Massachusetts General Hospital Cancer Center
    Harvard Medical School)

  • Jeffrey A. Engelman

    (Massachusetts General Hospital Cancer Center, Massachusetts General Hospital
    Harvard Medical School)

Abstract

Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, relapse typically occurs after an average of 1 year of continuous treatment. A fundamental histological transformation from NSCLC to small-cell lung cancer (SCLC) is observed in a subset of the resistant cancers, but the molecular changes associated with this transformation remain unknown. Analysis of tumour samples and cell lines derived from resistant EGFR mutant patients revealed that Retinoblastoma (RB) is lost in 100% of these SCLC transformed cases, but rarely in those that remain NSCLC. Further, increased neuroendocrine marker and decreased EGFR expression as well as greater sensitivity to BCL2 family inhibition are observed in resistant SCLC transformed cancers compared with resistant NSCLCs. Together, these findings suggest that this subset of resistant cancers ultimately adopt many of the molecular and phenotypic characteristics of classical SCLC.

Suggested Citation

  • Matthew J. Niederst & Lecia V. Sequist & John T. Poirier & Craig H. Mermel & Elizabeth L. Lockerman & Angel R. Garcia & Ryohei Katayama & Carlotta Costa & Kenneth N. Ross & Teresa Moran & Emily Howe &, 2015. "RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer," Nature Communications, Nature, vol. 6(1), pages 1-10, May.
    • Handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms7377
    DOI: 10.1038/ncomms7377
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/ncomms7377
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/ncomms7377?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Anna-Lisa Doebley & Minjeong Ko & Hanna Liao & A. Eden Cruikshank & Katheryn Santos & Caroline Kikawa & Joseph B. Hiatt & Robert D. Patton & Navonil De Sarkar & Katharine A. Collier & Anna C. H. Hoge , 2022. "A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    2. Ming Tang & Hussein A. Abbas & Marcelo V. Negrao & Maheshwari Ramineni & Xin Hu & Shawna Marie Hubert & Junya Fujimoto & Alexandre Reuben & Susan Varghese & Jianhua Zhang & Jun Li & Chi-Wan Chow & Xiz, 2021. "The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics," Nature Communications, Nature, vol. 12(1), pages 1-11, December.
    3. Han Wang & Huiying Sun & Bilin Liang & Fang Zhang & Fan Yang & Bowen Cui & Lixia Ding & Xiang Wang & Ronghua Wang & Jiaoyang Cai & Yanjing Tang & Jianan Rao & Wenting Hu & Shuang Zhao & Wenyan Wu & Xi, 2023. "Chromatin accessibility landscape of relapsed pediatric B-lineage acute lymphoblastic leukemia," Nature Communications, Nature, vol. 14(1), pages 1-15, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms7377. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.